LONDON, May 7 (Reuters) - British officials said on Friday people under 40 should be offered an alternative to Oxford/AstraZeneca's COVID-19 shot where possible due to a small risk of blood clots, given the low number of cases and the availability of other shots.
AstraZeneca's COVID-19 shot, developed by Oxford University, has resulted in reports of rare blood clots with low platelet levels that occur more commonly in younger adults. Some countries have advised the shot be given only to older people.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!